Summary
According to the recently published report 'Metabotropic Glutamate Receptor 5 - Drugs In Development, 2022'; Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) pipeline Target constitutes close to 19 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes.
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Metabotropic glutamate receptor 5 (mGluR5) is a G protein-coupled receptor. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling activates a phosphatidylinositol calcium second messenger system and generates a calcium activated chloride current. mGluR5 plays an important role in the regulation of synaptic plasticity and the modulation of the neural network activity.
The report 'Metabotropic Glutamate Receptor 5 - Drugs In Development, 2022' outlays comprehensive information on the Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 3, 3 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 5 molecules, respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders, Ophthalmology and Undisclosed which include indications Anxiety Disorders, Depression, Alzheimer's Disease, Blepharospasm, Fragile X Syndrome, Major Depressive Disorder, Pain, Parkinson's Disease, Schizophrenia, Substance (Drug) Abuse, Alcohol Addiction, Amyotrophic Lateral Sclerosis, Cognitive Impairment, Dementia, DiGeorge Syndrome, Drug Addiction, Dyskinesia, Dystonia, Seizures, Spasmodic Torticollis (Cervical Dystonia), Stammering (Stuttering), Trigeminal Neuralgia (Tic Douloureux) and Unspecified.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5)
- The report reviews Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics and enlists all their major and minor projects
- The report assesses Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Overview
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Allyx Therapeutics Inc
Appello Pharmaceuticals Inc
Bristol-Myers Squibb Co
Hua Medicine Shanghai Ltd
Laboratorio Farmaceutico CT Srl
Lactocore Inc
Nobias Therapeutics Inc
Noema Pharma AG
Novartis AG
Park of Active Molecules
Tempero Bio
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Drug Profiles
alloswitch-1 - Drug Profile
Product Description
Mechanism Of Action
ALX-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AP-612 - Drug Profile
Product Description
Mechanism Of Action
basimglurant - Drug Profile
Product Description
Mechanism Of Action
History of Events
BMS-952048 - Drug Profile
Product Description
Mechanism Of Action
dipraglurant - Drug Profile
Product Description
Mechanism Of Action
History of Events
dipraglurant ER - Drug Profile
Product Description
Mechanism Of Action
dipraglurant IR - Drug Profile
Product Description
Mechanism Of Action
History of Events
GET-73 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HTL-0014242 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LCGM-10 - Drug Profile
Product Description
Mechanism Of Action
mavoglurant - Drug Profile
Product Description
Mechanism Of Action
History of Events
mGLUR5 NAM - Drug Profile
Product Description
Mechanism Of Action
NB-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PAM-12 - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Agonize mGluR5 for Schizophrenia - Drug Profile
Product Description
Mechanism Of Action
VU-0092273 - Drug Profile
Product Description
Mechanism Of Action
VU-0431316 - Drug Profile
Product Description
Mechanism Of Action
VU-0467558 - Drug Profile
Product Description
Mechanism Of Action
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Dormant Products
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Discontinued Products
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Product Development Milestones
Featured News & Press Releases
Sep 06, 2022: Noema Pharma announces completion of enrollment in the Trigeminal Neuralgia Electronic Diary (TNED) validation study
Jun 17, 2022: Addex terminates dipraglurant phase 2b/3 study in patients with dyskinesia associated with Parkinson’s disease due to slow recruitment rate
May 27, 2022: Addex provides update on dipraglurant blepharospasm phase 2 feasibility clinical study
Apr 13, 2022: Addex Therapeutics completes patient enrollment for dipraglurant blepharospasm phase 2 clinical study
Feb 22, 2022: Noema Pharma announces first patient dosed in Phase 2b LibraTN study of mGluR5 inhibitor NOE-101 in trigeminal neuralgia
Feb 14, 2022: Noema Pharma announces FDA Investigational New Drug Authorization for Phase 2b LibraTN study of mGluR5 inhibitor NOE-101 in trigeminal neuralgia
Sep 29, 2021: Addex Therapeutics initiates phase 2 clinical study with Dipraglurant in blepharospasm
Jul 07, 2021: Noema Pharma to host a key opinion leader webinar on seizures in tuberous sclerosis complex
Jun 29, 2021: Addex Therapeutics initiates pivotal phase 2b/3 study with dipraglurant for dyskinesia associated with Parkinson’s Disease
May 17, 2021: Addex’s Dipraglurant restores synaptic plasticity in models of Dystonia
Mar 18, 2020: Addex Therapeutics delays start of Dipraglurant pivotal study and reporting 2019 full year audited results
Jan 17, 2019: Experimental drug improves eye gaze behavior in fragile X syndrome
Dec 13, 2018: Sosei Heptares starts new clinical development program - First subject dosed in Phase I study of HTL0014242, a selective mGlu5 negative allosteric modulator in development to treat psychiatric and neurological disorders
Oct 18, 2017: Van Leeuwenhoeck Issues Initiation of Coverage Research Report on Addex Therapeutics and Estimated ADXN Share Price of CHF 11.5 per Share
Feb 06, 2017: Addex's Clinical Programs and Discovery Platform Highlighted in Review of Allosteric Modulators for the Treatment of Neurodegenerative Diseases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Addex Therapeutics Ltd, 2022
Pipeline by Allyx Therapeutics Inc, 2022
Pipeline by Appello Pharmaceuticals Inc, 2022
Pipeline by Bristol-Myers Squibb Co, 2022
Pipeline by Hua Medicine Shanghai Ltd, 2022
Pipeline by Laboratorio Farmaceutico CT Srl, 2022
Pipeline by Lactocore Inc, 2022
Pipeline by Nobias Therapeutics Inc, 2022
Pipeline by Noema Pharma AG, 2022
Pipeline by Novartis AG, 2022
Pipeline by Park of Active Molecules, 2022
Pipeline by Tempero Bio, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Dormant Products, 2022 (Contd..3)
Discontinued Products, 2022
Discontinued Products, 2022 (Contd..1)
List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
